Form 4: VolitionRx CEO Veterinary Unit's Stock Transactions

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported an acquisition of 33,991 restricted stock units and a disposition of 99,350 common shares.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary at VolitionRx Ltd (VNRX), reported transactions on August 15, 2025.
• Acquired 33,991 restricted stock units (RSUs) under the Issuer's 2015 Stock Incentive Plan.
• The RSUs were awarded in lieu of cash compensation.
• The RSUs will be earned in six approximately equal monthly installments starting September 1, 2025.
• Vesting will occur in two installments: 16,996 units on November 1, 2025, and 16,995 units on February 1, 2026.
• Disposed of 99,350 shares of common stock.
• Following these transactions, the reporting person beneficially owns 337,515 shares of common stock.
• The 99,350 disposed shares were jointly owned with the reporting person's spouse.

Sentiment

Score: 6

Explanation: The filing indicates routine insider transactions. The RSU award in lieu of cash is a positive for company cash flow, while the share disposition is a neutral to slightly negative signal, but common for personal financial planning. Overall, it's a standard compensation and personal transaction disclosure.

Positives

• Award of 33,991 restricted stock units (RSUs) to a key executive, indicating continued alignment of interests with shareholders.
• The RSU award was in lieu of cash compensation, potentially conserving cash for the company.

Negatives

• Disposition of 99,350 common shares by a key executive.

Future Outlook

The awarded restricted stock units (RSUs) will be earned in six approximately equal monthly installments starting September 1, 2025, and will vest in two installments on November 1, 2025, and February 1, 2026, subject to continued service.

Industry Context

NA

Stakeholder Impact

• Shareholders: The RSU award aligns executive interests with shareholder value, while the share disposition is a personal financial decision by an executive.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: The RSU award in lieu of cash compensation could slightly benefit company cash flow, indirectly benefiting creditors.

Next Steps

• RSUs to be earned in six approximately equal monthly installments commencing September 1, 2025.
• First RSU vesting installment of 16,996 units on November 1, 2025.
• Second RSU vesting installment of 16,995 units on February 1, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically an RSU award as part of executive compensation and a disposition of shares. While the RSU award aligns executive incentives with shareholder value and conserves company cash, the share disposition is a personal financial decision and does not inherently signal a change in the company's fundamental outlook. There is no new material information regarding the company's operations, financial performance, or strategic direction that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate as this filing does not provide a strong catalyst for either buying or selling.

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU, Salvatore Thomas Butera, CEO Volition Veterinary, Equity Compensation